| Literature DB >> 21576196 |
Katerina K Naka1, Katerina Papathanassiou, Aris Bechlioulis, Konstantinos Pappas, Nikolaos Kazakos, Chryssanthi Kanioglou, Michail I Papafaklis, Aggeliki Kostoula, Patra Vezyraki, Demetrios Makriyiannis, Agathocles Tsatsoulis, Lampros K Michalis.
Abstract
An increased incidence of myocardial infarction with rosiglitazone in patients with type 2 diabetes mellitus (T2DM) has been reported. This study aimed to assess the effect of rosiglitazone on endothelial function, assessed by flow-mediated dilation (FMD), in 34 patients with advanced T2DM treated with insulin without known cardiovascular disease. Patients were randomised into two groups: no additional treatment was given in 17 patients, while 17 patients were given rosiglitazone for 6 months. Addition of rosiglitazone significantly reduced glycosylated haemoglobin (HbA(1c)) (p < 0.0005) and fasting glucose (p < 0.05) and improved FMD (p < 0.005). No significant changes were observed in the insulin-only group. The single independent predictor of FMD improvement was rosiglitazone treatment (p = 0.048). These results show that, in patients with advanced T2DM treated with insulin, addition of rosiglitazone may have a beneficial effect on endothelial function. Further research is needed to investigate why this beneficial effect does not translate into improved cardiovascular prognosis in these patients.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21576196 DOI： 10.1177/1479164111408628
Source DB: PubMed Journal: Diab Vasc Dis Res ISSN： 1479-1641 Impact factor: 3.291